Literature DB >> 21848619

Effect of cyclooxygenase inhibitors in a xenograft model of canine mammary tumours.

K Sonzogni-Desautels1, D W Knapp, E Sartin, M Doré.   

Abstract

Inhibition of cyclooxygenase-2 (COX-2) represents a possible avenue for the prevention and/or treatment of some cancers. Our goal was to compare the effect of a selective inhibitor of COX-2, deracoxib, and a COX-1 and -2 inhibitor, piroxicam, on the growth of canine mammary tumours in a murine model. CMT-9 was used to induce xenografts in nude mice. Mice were treated with piroxicam (0.6 mg kg(-1)), deracoxib (6 mg kg(-1)) or a control solution. Tumour volumes between 0 and 24 days post-treatment showed no significant difference between all groups. A second series of experiments was performed with a higher dose of piroxicam (0.9 mg kg(-1)). Tumour volumes between 14 and 21 days post-treatment were significantly smaller in piroxicam-treated mice compared with controls. These results demonstrate that COX inhibition reduced the growth of canine mammary cancer xenografts in mice, suggesting that COX inhibitors could have a positive effect in dogs.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21848619     DOI: 10.1111/j.1476-5829.2010.00242.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  4 in total

1.  Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells.

Authors:  María P Iturriaga; Rodolfo Paredes; Jose I Arias; Cristian G Torres
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

2.  The effects of piroxicam and deracoxib on canine mammary tumour cell line.

Authors:  Fulya Ustün Alkan; Oya Ustüner; Tülay Bakırel; Suzan Cınar; Gaye Erten; Günnur Deniz
Journal:  ScientificWorldJournal       Date:  2012-11-07

Review 3.  Pathobiology of Hemangiosarcoma in Dogs: Research Advances and Future Perspectives.

Authors:  Jong-Hyuk Kim; Ashley J Graef; Erin B Dickerson; Jaime F Modiano
Journal:  Vet Sci       Date:  2015-11-06

4.  BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway.

Authors:  Melissa M Ledet; Robyn Anderson; Rebecca Harman; Aaron Muth; Paul R Thompson; Scott A Coonrod; Gerlinde R Van de Walle
Journal:  BMC Cancer       Date:  2018-04-12       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.